← All devices 
Clinical / medical-grade · Patch / sensor · by SiBionics
SiBionics GS3
An ultra-thin CGM marketed as the world’s thinnest — CE-marked in Europe, but not FDA-cleared or sold in the US.
March 2025SiBionics GS3
Fresh in cycle1 yr 3 mo old
API access: No Raw data access: Yes — restricted Open source: No public repo
Clinical value
70/100
CE-marked CGM (not US FDA)
Empowerment
48/100
App-based; not US-available
Everyday value
56/100
Ultra-thin 14-day sensor
A continuous glucose monitor from China-based SiBionics, marketed as the world’s thinnest CGM with three-second activation and CE marking — but not FDA-cleared and not sold in the US.
What it measures
Continuous interstitial glucose via a slim (~2.9 mm) adhesive arm sensor with an app, typically up to ~14-day wear.
Regulatory status
CE-marked in Europe (2025); not FDA-cleared and outside the US prescription/OTC framework — not US-available.
Validation & accuracy
Marketed accuracy claims; limited independent peer-reviewed validation published outside company materials.
Data control & export
Raw data: restricted — app-based readings and trends; no documented open export or US data pathway. API: none.
Wearability & battery
A very thin, coin-sized adhesive arm sensor; no charging, replaced each cycle.
Cost & access
Sold in Europe (direct/online); not available in the US.
Who it serves
EU/international users seeking a low-cost, ultra-thin CGM.
Who is left out or burdened
No US FDA clearance or availability; limited independent validation; app-locked data.
✓ Strengths
- Marketed as the world’s thinnest CGM (~2.9 mm)
- CE-marked in Europe; three-second activation
- Low-cost relative to incumbents
- Continuous glucose with app trends
✕ Weaknesses
- Not FDA-cleared or sold in the US
- Limited independent validation
- App-locked data; no open export
- No US support or insurance pathway
70
Why this clinical score. A CE-marked CGM is clinically capable, but no US FDA clearance, limited public validation, and no US availability hold it mid-axis.
48
Why this empowerment score. App-locked data, no US availability, and no open export keep empowerment low-mid.
56
Why this everyday score. An ultra-thin, comfortable sensor, but unavailable to US patients.
Latest news
Reviews & coverage
Reviewers describe SiBionics as an emerging low-cost CGM gaining traction outside the US, with a usable app and competitive accuracy claims. Caveats are limited independent validation and patchy regional availability/support.
Summary is a draft synthesis of public coverage, not an endorsement. Links open a search of each outlet.
Reddit communities
Independent user communities where this device (or its category) is discussed.
Get it · manuals & support
Draft profile · public-source review, June 2026 · scores describe direction and degree, not buying advice. News, links, and prices change — verify with the manufacturer. Image is representative.